2nd Proteomics-Based Drug Discovery Summit 2026

 

With major deals like Novartis’ $750M partnership with ProFound Therapeutics and Illumina’s $425M acquisition of SomaLogic, proteomics is rapidly emerging as a transformative force in drug discovery.

Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit unites 70+ leaders in proteomics, chemical biology, mass spectrometry, and bioinformatics. Attendees will explore how next-generation proteomic platforms accelerate target discovery, pathology understanding, and hit-to-lead development.

With sessions on optimizing instruments, automating workflows, PTM analysis, and establishing gold-standard methodologies, this premier forum will empower innovators to expand the druggable proteome and drive breakthroughs for diseases with unmet clinical needs.

More Info

---

---